Levodopa for Parkinson's disease. 2009

Jean Marie Gérard, and José-Antonio Elosegi

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson
D017072 Neostriatum The phylogenetically newer part of the CORPUS STRIATUM consisting of the CAUDATE NUCLEUS and PUTAMEN. It is often called simply the striatum.

Related Publications

Jean Marie Gérard, and José-Antonio Elosegi
February 2009, The New England journal of medicine,
Jean Marie Gérard, and José-Antonio Elosegi
November 2016, CNS drugs,
Jean Marie Gérard, and José-Antonio Elosegi
March 2014, Movement disorders : official journal of the Movement Disorder Society,
Jean Marie Gérard, and José-Antonio Elosegi
December 2022, The Lancet. Neurology,
Jean Marie Gérard, and José-Antonio Elosegi
May 2019, The Medical letter on drugs and therapeutics,
Jean Marie Gérard, and José-Antonio Elosegi
June 2007, Neuropsychiatric disease and treatment,
Jean Marie Gérard, and José-Antonio Elosegi
August 1999, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
Jean Marie Gérard, and José-Antonio Elosegi
January 1971, Duodecim; laaketieteellinen aikakauskirja,
Jean Marie Gérard, and José-Antonio Elosegi
January 2002, The Cochrane database of systematic reviews,
Jean Marie Gérard, and José-Antonio Elosegi
October 2007, The Cochrane database of systematic reviews,
Copied contents to your clipboard!